Danaher Corporation $DHR Shares Sold by Fulton Breakefield Broenniman LLC

Fulton Breakefield Broenniman LLC decreased its stake in Danaher Corporation (NYSE:DHR) by 6.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 66,948 shares of the conglomerate’s stock after selling 4,727 shares during the period. Fulton Breakefield Broenniman LLC’s holdings in Danaher were worth $13,273,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. White Pine Capital LLC boosted its stake in Danaher by 1.4% in the second quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock valued at $690,000 after acquiring an additional 49 shares in the last quarter. Boyd Watterson Asset Management LLC OH boosted its position in shares of Danaher by 2.1% in the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after purchasing an additional 51 shares during the period. Worth Financial Advisory Group LLC boosted its position in shares of Danaher by 4.6% in the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after purchasing an additional 53 shares during the period. Howard Capital Management Group LLC grew its stake in Danaher by 4.8% during the 3rd quarter. Howard Capital Management Group LLC now owns 1,159 shares of the conglomerate’s stock worth $230,000 after buying an additional 53 shares during the last quarter. Finally, Bruce G. Allen Investments LLC increased its position in Danaher by 13.1% during the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after buying an additional 54 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Teri List sold 3,298 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the sale, the director owned 20,762 shares of the company’s stock, valued at $4,702,593. This trade represents a 13.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,248 shares of company stock valued at $6,609,663 over the last quarter. Company insiders own 11.10% of the company’s stock.

Danaher Stock Down 0.4%

DHR stock opened at $230.52 on Friday. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The company has a fifty day moving average of $222.66 and a 200-day moving average of $208.15. The stock has a market capitalization of $162.83 billion, a PE ratio of 47.53, a price-to-earnings-growth ratio of 4.48 and a beta of 0.89.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same period in the prior year, the company posted $1.71 earnings per share. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. As a group, analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on DHR shares. Deutsche Bank Aktiengesellschaft increased their price objective on Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. JPMorgan Chase & Co. increased their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of Danaher in a research report on Monday. Evercore ISI upped their target price on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Finally, Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Twenty-one research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $248.25.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.